Advocacy | SMA Europe

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

SMA Europe responds to European neuromuscular experts’ consensus statements on gene replacement therapy for SMA
A group of European neuromuscular experts presented eleven consensus statements covering qualification, patient selection, safety considerations and long-term monitoring, in order to aid the rational use of Zolgensma™ for the treatment of SMA (1). In a letter published in the European Journal of Paediatric Neurology (2), SMA Europe addresses these consensus statements by highlights: The […]
READ MORE
Announcing the launch of the European Alliance for Newborn Screening for Spinal Muscular Atrophy (SMA NBS Alliance)
Opening a new horizon for children born with SMA On 31 August 2020, the last day of SMA Awareness Month, SMA Europe is proud to announce the launch of a new European Alliance for Newborn Screening (NBS) in Spinal Muscular Atrophy (SMA). The Alliance’s main objectives are to decrease the time it takes for a […]
READ MORE

News

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

SMA Europe responds to European neuromuscular experts’ consensus statements on gene replacement therapy for SMA

Announcing the launch of the European Alliance for Newborn Screening for Spinal Muscular Atrophy (SMA NBS Alliance)

Essentials Informations

Publications